BR112015017331A2 - compostos químicos - Google Patents

compostos químicos

Info

Publication number
BR112015017331A2
BR112015017331A2 BR112015017331A BR112015017331A BR112015017331A2 BR 112015017331 A2 BR112015017331 A2 BR 112015017331A2 BR 112015017331 A BR112015017331 A BR 112015017331A BR 112015017331 A BR112015017331 A BR 112015017331A BR 112015017331 A2 BR112015017331 A2 BR 112015017331A2
Authority
BR
Brazil
Prior art keywords
chemical compounds
compounds
processes
pharmaceutically acceptable
formula
Prior art date
Application number
BR112015017331A
Other languages
English (en)
Other versions
BR112015017331B1 (pt
BR112015017331A8 (pt
Inventor
Delouvrie Benedicte
Christophe Barlaam Bernard
Marie Paul Lambert-Van Der Brempt Christine
Steven Harris Craig
Berry David
Patrick Reid Gary
Peter Tomkinson Gary
Ouvry Gilles
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112015017331A2 publication Critical patent/BR112015017331A2/pt
Publication of BR112015017331A8 publication Critical patent/BR112015017331A8/pt
Publication of BR112015017331B1 publication Critical patent/BR112015017331B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "compostos químicos". a presente invenção refere-se a compostos de fórmula (i): ou a sais farmaceuticamente aceitáveis dos mesmos, em que r1 e r2 têm qualquer um dos significados definidos aqui antes na descrição; a processos para seu preparo, a composições farmacêuticas contendo os mesmos e a seu uso no tratamento de distúrbios proliferativos celulares.
BR112015017331-4A 2013-01-23 2014-01-22 Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição BR112015017331B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305078 2013-01-23
EP13305078.1 2013-01-23
PCT/GB2014/050163 WO2014114928A1 (en) 2013-01-23 2014-01-22 Chemical compounds

Publications (3)

Publication Number Publication Date
BR112015017331A2 true BR112015017331A2 (pt) 2017-07-11
BR112015017331A8 BR112015017331A8 (pt) 2019-11-12
BR112015017331B1 BR112015017331B1 (pt) 2022-01-11

Family

ID=47623992

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017331-4A BR112015017331B1 (pt) 2013-01-23 2014-01-22 Compostos de formula i, forma cristalina, uso dos compostos, combinação e composição

Country Status (27)

Country Link
US (2) US9156831B2 (pt)
EP (1) EP2948447B1 (pt)
JP (1) JP6307096B2 (pt)
KR (1) KR102202516B1 (pt)
CN (1) CN104936953B (pt)
AP (1) AP2015008604A0 (pt)
AR (1) AR094553A1 (pt)
AU (1) AU2014208964B2 (pt)
BR (1) BR112015017331B1 (pt)
CA (1) CA2897279C (pt)
CL (1) CL2015002027A1 (pt)
CR (1) CR20150367A (pt)
DO (1) DOP2015000170A (pt)
ES (1) ES2608395T3 (pt)
HK (1) HK1214592A1 (pt)
IL (1) IL239890A0 (pt)
MA (1) MA38287B1 (pt)
MX (1) MX361136B (pt)
NI (1) NI201500096A (pt)
PE (1) PE20151979A1 (pt)
PH (1) PH12015501584A1 (pt)
RU (1) RU2644769C2 (pt)
SG (1) SG11201505631PA (pt)
TN (1) TN2015000313A1 (pt)
TW (1) TWI606047B (pt)
UY (1) UY35275A (pt)
WO (1) WO2014114928A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
TW201726140A (zh) * 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN107137405A (zh) * 2017-04-14 2017-09-08 黄德莲 一种治疗肾炎的药物组合物
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种***-羧酸酯类衍生物在医药领域的应用
WO2020094363A1 (en) 2018-11-05 2020-05-14 Syngenta Participations Ag Pesticidally active azole-amide compounds
US20220033775A1 (en) 2018-11-05 2022-02-03 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathways inhibitors
ES2953140T3 (es) 2019-03-08 2023-11-08 Syngenta Crop Protection Ag Compuestos de azol-amida activos de manera plaguicida
WO2020188014A1 (en) 2019-03-20 2020-09-24 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
US20220213063A1 (en) 2019-03-22 2022-07-07 Syngenta Crop Protection Ag N-[l-(5-BROMO-2-PYRIMIDIN-2-YL-1,2,4-TRIAZOL-3-YL)ETHYL]-2-CYCLOPROPYL-6-(TRIFLUOROMETHYL)PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES
EP4138787A1 (en) 2020-04-24 2023-03-01 Astrazeneca AB Pharmaceutical formulations

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (pt) 1970-09-25 1972-03-28
US4256887A (en) 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP3028168B2 (ja) 1993-03-29 2000-04-04 住化ファインケム株式会社 ベンゼンスルホンアミド誘導体の製造方法
US5656416A (en) 1994-12-22 1997-08-12 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
CA2212061A1 (en) 1995-02-02 1996-08-08 Laramie Mary Gaster Indole derivatives as 5-ht receptor antagonist
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
AU724076B2 (en) 1996-07-25 2000-09-14 Merck Sharp & Dohme Limited Substituted triazolo pyridazine derivatives as inverse agonists of the GABAAalpha5 receptor subtype
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
MXPA03000504A (es) 2000-07-19 2003-06-24 Hoffmann La Roche Derivados de pirimidina.
ES2333586T3 (es) 2001-11-21 2010-02-24 PHARMACIA & UPJOHN COMPANY LLC Derivados de aril 1,4-pirazina sustituidos.
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
US7408067B2 (en) 2002-01-17 2008-08-05 Merck + Co., Inc. Aza-cyclic compounds as modulators of acetylcholine receptors
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
GB0306097D0 (en) 2003-03-15 2003-04-23 Elam T Ltd Electroluminescent complexes
JP2006520794A (ja) 2003-03-21 2006-09-14 スミスクライン ビーチャム コーポレーション 化合物
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
KR101164541B1 (ko) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
DE602005019556D1 (de) 2004-04-13 2010-04-08 Icagen Inc Polycyclische pyrazine als kaliumionenkanal-modulatoren
JP2006028056A (ja) 2004-07-14 2006-02-02 Agro Kanesho Co Ltd ピリミジン誘導体及びこれを含む有害生物防除剤
JP4982367B2 (ja) 2004-07-26 2012-07-25 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体薬剤としてのオキサゾール誘導体、製造及び治療的使用
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
CA2610888C (en) 2005-06-10 2011-02-08 Merck & Co., Inc. Inhibitors of akt activity
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
MX2008012096A (es) 2006-03-22 2008-12-17 Vertex Pharma Inhibidores de proteina cinasa c-met para el tratamiento de trastornos proliferativos.
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
RU2009101911A (ru) 2006-06-22 2010-07-27 Биовитрум Аб (Пабл) (Se) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
DK2034839T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Res TREATMENT OF NEURODEGENERATIVE DISEASES BY INHIBITION OF HSP90
JP2009544626A (ja) 2006-07-21 2009-12-17 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｉｔｐｋｂ阻害剤としての化合物および組成物
HUE033894T2 (en) 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
EP2151437A4 (en) 2007-03-07 2012-05-02 Nissan Chemical Ind Ltd ISOXAZOLINE SUBSTITUTED BENZAMIDE COMPOUND AND PEST CONTROL AGENT
MY169738A (en) 2007-08-14 2019-05-14 Bayer Ip Gmbh Fused bicyclic pyrimidines
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
PT2201012E (pt) 2007-10-11 2014-09-04 Astrazeneca Ab Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
EP2230230A4 (en) 2007-12-07 2011-03-16 Nissan Chemical Ind Ltd SUBSTITUTED DIHYDROAZOL COMPOUND AND PESTICIDES
WO2009080705A2 (en) 2007-12-20 2009-07-02 Novartis Ag Bis-thiazole derivatives, process for their preparation and their use as medicaments
EP2234618A4 (en) 2007-12-21 2011-04-27 Scripps Research Inst BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS
EP2310391A1 (en) * 2008-06-27 2011-04-20 S*BIO Pte Ltd Pyrazine substituted purines
WO2010026121A1 (en) 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
JP2010083883A (ja) 2008-09-08 2010-04-15 Nissan Chem Ind Ltd イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2010063863A (ja) 2008-09-11 2010-03-25 Mugen:Kk ヘッドのフェース部背面に音響振動の異なるパイプまたは平板を複数設けた打点位置表示型ゴルフ練習用クラブとその製法
CN101676271B (zh) 2008-09-17 2011-12-14 山东轩竹医药科技有限公司 含有不饱和杂环胺的四环素衍生物
KR20170015566A (ko) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
AU2009316019A1 (en) * 2008-11-14 2010-05-20 Bayer Intellectual Property Gmbh Heterocyclically substituted aryl compounds as HIF inhibitors
KR101745331B1 (ko) * 2008-12-19 2017-06-09 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 피라진 유도체
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
CA2752114C (en) * 2009-02-13 2017-06-20 Bayer Pharma Aktiengesellschaft Fused pyrimidines as akt inhibitors
SG172898A1 (en) 2009-02-13 2011-08-29 Bayer Schering Pharma Ag Fused pyrimidines
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011025690A1 (en) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
AU2010309882B2 (en) 2009-10-20 2016-01-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
CA2789021C (en) 2010-02-05 2018-02-06 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
JP2011178673A (ja) 2010-02-26 2011-09-15 Nissan Chem Ind Ltd 非農園芸害虫の防除方法
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
KR20130066633A (ko) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
WO2012037226A1 (en) * 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2012034526A1 (en) * 2010-09-16 2012-03-22 Hutchison Medipharma Limited Fused heteroaryls and their uses
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
AU2012258618B2 (en) 2011-05-26 2017-05-25 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
WO2013049591A2 (en) 2011-09-29 2013-04-04 Verseon Corporation Dual inhibitor compounds and methods of use thereof
JP2015515478A (ja) 2012-04-05 2015-05-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物及びそれらの併用療法

Also Published As

Publication number Publication date
IL239890A0 (en) 2015-08-31
CN104936953B (zh) 2017-03-08
CR20150367A (es) 2015-10-20
AU2014208964A1 (en) 2015-08-06
DOP2015000170A (es) 2015-08-16
NI201500096A (es) 2016-02-16
RU2015132370A (ru) 2017-03-02
KR20150109385A (ko) 2015-10-01
CN104936953A (zh) 2015-09-23
CA2897279A1 (en) 2014-07-31
US20140206700A1 (en) 2014-07-24
AU2014208964B2 (en) 2016-09-01
TWI606047B (zh) 2017-11-21
US20160137634A1 (en) 2016-05-19
JP6307096B2 (ja) 2018-04-04
PE20151979A1 (es) 2016-01-15
PH12015501584A1 (en) 2015-10-05
EP2948447B1 (en) 2016-09-21
CL2015002027A1 (es) 2015-11-13
CA2897279C (en) 2020-12-29
KR102202516B1 (ko) 2021-01-12
US9657008B2 (en) 2017-05-23
MX2015009465A (es) 2015-09-28
UY35275A (es) 2014-07-31
AP2015008604A0 (en) 2015-07-31
WO2014114928A1 (en) 2014-07-31
TN2015000313A1 (en) 2017-01-03
ES2608395T3 (es) 2017-04-10
TW201522329A (zh) 2015-06-16
JP2016508484A (ja) 2016-03-22
MX361136B (es) 2018-11-28
US9156831B2 (en) 2015-10-13
SG11201505631PA (en) 2015-08-28
RU2644769C2 (ru) 2018-02-14
MA38287A1 (fr) 2018-01-31
BR112015017331B1 (pt) 2022-01-11
AR094553A1 (es) 2015-08-12
MA38287B1 (fr) 2018-08-31
EP2948447A1 (en) 2015-12-02
BR112015017331A8 (pt) 2019-11-12
HK1214592A1 (zh) 2016-07-29

Similar Documents

Publication Publication Date Title
BR112015017331A2 (pt) compostos químicos
BR112015029455A2 (pt) compostos químicos
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
BR112019007393A2 (pt) derivados 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento de câncer
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
BR112015008325A2 (pt) compostos antivirais contra o rsv
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
BR112012031561A2 (pt) morfolino pirimidinas e seu uso em terapia.
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112015028538A2 (pt) derivados de sulfamoiltiofenamida e o uso dos mesmos como medicamentos para o tratamento da hepatite b
BR112015004205A2 (pt) sulfamoil-arilamidas e o uso das mesmas como medicamentos para o tratamento da hepatite b
BR112013026397A2 (pt) Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer
BR112013019714A2 (pt) azaindolilfenil sulfonamidas como inibidores de serina/treonina quinase
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015027951A8 (pt) arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BR112014015845A2 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112013002587A2 (pt) compostos químicos
BR112013031402A2 (pt) derivados de hidantoína como inibidores de kv3
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2014, OBSERVADAS AS CONDICOES LEGAIS.